No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RVPH240719P5500
- 4.45
- 0.000.00%
15min DelayClose Jul 17 15:58 ET
0.00High0.00Low
4.45Open4.45Pre Close0 Volume1 Open Interest5.50Strike Price0.00Turnover0.00%IV12.13%PremiumJul 19, 2024Expiry Date4.31Intrinsic Value100Multiplier2DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.28Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Reviva Pharm Holdings Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Reviva Pharm Holdings Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Express News | Reviva Granted A European Patent Covering The Use Of Brilaroxazine In Treatment Of Pulmonary Hypertension
Express News | Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $14 price target.
H.C. Wainwright Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $14
H.C. Wainwright analyst Ram Selvaraju maintains $Reviva Pharmaceuticals(RVPH.US)$ with a buy rating, and adjusts the target price from $20 to $14.According to TipRanks data, the analyst has a success
Reviva Pharm Holdings Is Maintained at Buy by HC Wainwright & Co.
Reviva Pharm Holdings Is Maintained at Buy by HC Wainwright & Co.
Comments
$Reviva Pharmaceuticals(RVPH.US$ Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
$Reviva Pharmaceuticals(RVPH.US$ Reviva Announces Closing of $3 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
4
$Reviva Pharmaceuticals(RVPH.US$ Reviva Pharmaceuticals Holdings, Inc. -Topline Data From 1-Year Open-Label Extension (Ole) Trial Expected in Q4 2024
$Reviva Pharmaceuticals(RVPH.US$ Reviva Announces Alignment With FDA On Brilaroxazine Clinical Trials For NDA In Schizophrenia; FDA Accepts 4-Week RECOVER-2 Study
2
$Reviva Pharmaceuticals(RVPH.US$ H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) today and set a price target of $20.00.
1
Read more